ABSTRACT
Objective To explore the changes in the serum periostin (PN) and vascular endothelial growth factor (VEGF) level in patients with diabetic retinopathy (DR) and the clinical significance.Methods The serum samples from 53 patients with diabetes mellitus (DM) as case group and 50 healthy subjects as control group were collected and compared in this study.And the DM patients included 15 patients with DM without fundus lesions (DM group),18 patients with non-proliferative diabetic retinopathy (NPDR,NPDR group) and 20 patients with proliferative diabetic retinopathy (PDR,PDR group).The serum levels of PN and VEGF were analyzed by ELISA assay,and the correlation of DR with serum PN and VEGF levels was evaluated.Results The differences in serum PN and VEGF between the case group and control group were statistically significant (both P ＜ 0.05).And there were significant difference in PN and VEGF levels among the DM group,NPDR group,PDR group and control group (all P ＜ 0.05).Meanwhile,there was no significant difference in serum PN between the DM group and NPDR group (P ＞ 0.05),but there were statistically significant differences among the other groups (all P ＜ 0.05).There were statistically significant differences in serum VEGF among the four groups (all P ＜ 0.05).And finally,positive correlations were found between PN and VEGF in the NPDR group and PDR group (r =0.483,0.509,both P ＜ 0.05).Conclusion PN and VEGF play an active role in the initiation and development of DR,and they have a close correlation with the neovascularization and fibrovascular membrane of the advanced stage of DR.
ABSTRACT
· AIM:To investigate the clinical effect of Ranibizumab combined with photodynamic therapy (PDT) for wet type age-related macular degeneration (wAMD) and the effect on the serum neovascularization factors.· METHODS:Totally 68 cases (68 eyes) of wAMD patients treated with PDT in our hospital from January 2014 to June 2016 were analyzed retrospectively.Among them,34 patients were treated by photodynamic therapy (control group) and 34 patients were treated by combination of photodynamic therapy and ranibizumab (treatment group).Comparison of BCVA,mean retinal thickness and central macular thickness (CMT) and serum neovascularization regulatory factors before and after treatment were taken between the two groups.· RESULTS:Before treatment,there was no significant difference on the BCVA,the average retinal thickness and the CMT value between the two groups (P＞0.05).At 3,6 and 12mo after treatment,the BCVA,average retinal thickness and CMT in both groups were significantly lower than those before treatment (P＜0.05).At 3,6 and 12mo after treatment,the BCVA,the average retinal thickness and the CMT value of the patients in the treatment group were significantly lower than those in the control group (P＜0.05).There was no significant difference of vascular endothelial growth factor (VEGF),platelet derived growth factor (PDGF),matrix metallo-proteinase inhibitor (TIMP)-1 and endostatin (ES) between the two groups before treatment (P＞ 0.05).Three months after treatment,VEGF,PDGF and ES in both groups were significantly lower than those before treatment (P＜0.05).Three months after treatment,the levels of VEGF,PDGF and ES in the treatment group were significantly lower than those in the control group (P＜0.05).· CONCLUSION:The wAMD patients treated with ranibizumab combined with photodynamic therapy can achieve a more significant clinical effect,and more effectively reduce the level of serum neovascularization regulators.